Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Human Genetics, |
RCV000768475 | SCV000886763 | likely pathogenic | Hypertrophic cardiomyopathy | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004027156 | SCV005033772 | pathogenic | Cardiovascular phenotype | 2024-01-23 | criteria provided, single submitter | clinical testing | The p.E872* pathogenic mutation (also known as c.2614G>T), located in coding exon 26 of the MYBPC3 gene, results from a G to T substitution at nucleotide position 2614. This changes the amino acid from a glutamic acid to a stop codon within coding exon 26. This alteration has been reported in association with hypertrophic cardiomyopathy (HCM) (Robyns T et al. Eur J Med Genet, 2020 Mar;63:103754; Harper AR et al. Nat Genet, 2021 Feb;53:135-142). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |